Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 40Neoplasms, Plasma Cell 5Neoplasms 5Recurrence 4Renal Insufficiency 3Paraproteinemias 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Blood Protein Disorders 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Cryoglobulinemia, Familial Mixed 1

Interventions

Cyclophosphamide 46fludarabine phosphate 34Peripheral Blood Stem Cell Transplantation 29Whole-Body Irradiation 22Etoposide 22Tacrolimus 20Methotrexate 20Mycophenolic Acid 19Cytarabine 19Dexamethasone 17Vincristine 16Filgrastim 16Busulfan 16venetoclax 15Antilymphocyte Serum 15Rituximab 13Prednisone 13Cyclosporine 12Doxorubicin 11Melphalan 9Calcium Dobesilate 9nelarabine 8Bortezomib 8merphos 7Radiotherapy 7Methylprednisolone 7Granulocyte Colony-Stimulating Factor 7Azacitidine 7prednylidene 6pegaspargase 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × isatuximab × Clear all
NCT06648889 2026-01-15

Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Goethe University

Phase 2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡